GSEP
EW icon

Golden State Equity Partners’s Edwards Lifesciences EW Stock Holding History

Golden State Equity Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8K Sell
42
-148
-78% -$12.4K 0.01% 264
2026
Q1 		$15.2K Buy
+190
New +$15.7K ﹤0.01% 1179

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Golden State Equity Partners's EW Position: Q2 2026 in Review

Golden State Equity Partners reduced its Edwards Lifesciences (EW) stake by 78% in Q2 2026, selling an estimated $12.4K and leaving 42 shares worth $3.8K. The position accounts for 0.01% of the portfolio, ranked #264.

Golden State Equity Partners first reported a position in EW in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.2K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Golden State Equity Partners held 42 shares of Edwards Lifesciences worth $3.8K as of Q2 2026.
  • Golden State Equity Partners sold 148 Edwards Lifesciences shares in Q2 2026, an estimated $12.4K.
  • Edwards Lifesciences made up 0.01% of Golden State Equity Partners's portfolio in Q2 2026, its #264 holding.
  • Golden State Equity Partners first reported a position in Edwards Lifesciences in Q1 2026 and has held it in 2 quarters since.
  • Golden State Equity Partners's Edwards Lifesciences position peaked at $15.2K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.